Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SOD3 | P08294 | 2/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038174 | 1.00 | CXCR4 (0.56) | CXCR4GNAO1GNAI3GNAI1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4390905 | 0.98 | GNAO1 (0.56) | CXCR4GNAO1GNAI3GNAI1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL27894273 | 0.98 | GNAO1 (0.56) | CXCR4GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL21299356 | 0.98 | CXCR4 (0.59) | CXCR4GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL6744648 | 0.98 | CXCR4 (0.59) | CXCR4GNAO1GNAI3GNAI1SIGMAR1 | |
| Piperazine SCHEMBL28239114 | 0.98 | CXCR4 (0.59) | CXCR4GNAO1GNAI3GNAI1SIGMAR1 | |
| Ammonia Solution, Strong SCHEMBL3391596 | 0.98 | CXCR4 (0.54) | CXCR4GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL19169974 | 0.98 | CXCR4 (0.59) | CXCR4GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL15656630 | 0.95 | CXCR4 (0.55) | CXCR4GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL9396737 | 0.93 | GNAO1 (0.61) | CXCR4GNAO1GNAI3GNAI1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080895-A | Polyglycolic acid composition and preparation method thereof, biodegradable polyester material and application thereof, and PGA temporary plugging ball and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122071631-A | Polyglycolic acid temporary plugging agent with controllable degradation rate and preparation method and application thereof | 中国石油化工股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| US-12595236-B2 | Pyrimidine-2,4-diamine compound and preparation method and application thereof | ANHUI MEDICAL UNIVERSITY (CN) | 2026-04-07 | — | — | US | claimed |
| US-12502386-B2 | Nitrogen-containing heterocyclic compound and use thereof | Shanghai Shijiang Biotechnology Co., Ltd. (CN) | 2025-12-23 | — | — | US | claimed |
| US-20250197389-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) | 2025-06-19 | — | — | US | claimed |
| US-20250197415-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) | 2025-06-19 | — | — | US | claimed |
| WO-2025098057-A1 | DEGRADATION-CONTROLLABLE TEMPORARY PLUGGING AGENT AND PREPARATION METHOD THEREFOR, DEGRADATION PERFORMANCE REGULATION AND CONTROL METHOD, AND USE | 中国石油化工股份有限公司 | 2025-05-15 | — | — | WO | claimed |
| CN-119955493-A | Controllable degradable polyglycolic acid temporary plugging agent, preparation method and temporary plugging agent degradation performance regulation and control method | 中国石油化工股份有限公司 | 2025-05-09 | — | — | CN | claimed |
| US-20250147425-A1 | STRIPPER COMPOSITION AND METHOD FOR FORMING PATTERN USING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-05-08 | — | — | US | claimed |
| CN-119937261-A | Release agent composition and method of forming pattern using the same | 三星显示有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-1318425-C | Cough and phlegm removing purple bergenia element analog and its pharmaceutical composition | SICHUAN DIHON MEDICAL DEV CO L (CN) | 2007-05-30 | — | — | CN | claimed |
| EP-1432717-B1 | SUBSTITUTED DISILOXANES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR REVERSAL OF MULTIDRUG RESISTANCE (MDR) | MOLNAR JOZSEF (HU) | 2006-03-01 | — | — | EP | claimed |
| CN-1733766-A | Cough and phlegm removing purple bergenia element analog and its pharmaceutical composition | SICHUAN DIHON MEDICAL DEV CO L (CN) | 2006-02-15 | — | — | CN | claimed |
| EP-1432717-A1 | SUBSTITUTED DISILOXANES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR REVERSAL OF MULTIDRUG RESISTANCE (MDR) | Molnar, Jozsef (HU) | 2004-06-30 | — | — | EP | claimed |
| WO-2002040490-A1 | SUBSTITUTED DISILOXANES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR REVERSAL OF MULTIDRUG RESISTANCE (MDR) | VARGA ANDRAS (DE) | 2002-05-23 | — | — | WO | claimed |
| US-5340823-A | Administering a muscle relaxants for treating parkinson*s disease | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1994-08-23 | — | — | US | claimed |
| US-5166433-A | Zirconium oxide, copper oxide, cobalt oxide or nickel oxide as catalysts for forming amines | BASF AKTIENGESELLSCHAFT (DE) | 1992-11-24 | — | — | US | claimed |
| EP-0385043-A1 | New derivatives of 4-substituted piperazines | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1990-09-05 | — | — | EP | claimed |
| US-4279912-A | ANTIALLERGENS, BRONCHODILATORS | ROUSSEL UCLAF (FR) | 1981-07-21 | — | — | US | claimed |
| US-4091115-A | ANTIDEPRESSANTS | ROUSSEL UCLAF (FR) | 1978-05-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197389-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | PPIF, PIN1, NME4 | CXCR4 1804/4885GNAO1 1380/4885GNAI3 796/4885 |
| US-12595236-B2 | Pyrimidine-2,4-diamine compound and preparation method and application thereof | CTSZ, CTSV, CASP2 | CXCR4 471/4885GNAO1 4042/4885GNAI3 4244/4885 |
| US-20250197415-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | UHRF1, NNMT, EHMT1 | CXCR4 3665/4885GNAO1 549/4885GNAI3 1276/4885 |
| US-12502386-B2 | Nitrogen-containing heterocyclic compound and use thereof | UHRF1, NNMT, EHMT1 | CXCR4 3665/4885GNAO1 549/4885GNAI3 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.